Ariceum Therapeutics
Germo Gericke's work experience began in 1994 as a Postdoctoral Fellow at Dartmouth Medical School, specializing in Immunology and Oncology. From 1995 to 2001, they worked as an Engagement Manager at McKinsey & Co., Inc. Their career then transitioned to Novartis, where they held various roles including Assistant to the Chairman and CEO, Marketing and Sales Rotation in US-Oncology, Business Unit Head in Transplantation & Immunology, Therapeutic Area Head in Project Management for Dermatology, GI & GU, and Franchise Global Program Head in Oncology Global Development and Medical Affairs. From 2018 to 2020, Germo served as the Global Head of Research & Development and subsequently as the Chief Medical Officer at Advanced Accelerator Applications, a Novartis Company. Currently, they hold the position of Chief Medical Officer at Ariceum Therapeutics since February 2023.
Germo Gericke pursued their Doctor of Medicine (M.D.) degree in Medicine from Humboldt-Universität zu Berlin, which they completed between 1987 and 1993. Additionally, from 1990 to 1993, they attended Heidelberg University, where they obtained a Doctor of Medicine - M.D. degree with a specialization in Immunology/Oncology.
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.